source
- FDA reprimands Lundbeck Seattle Biopharmaceuticals for inflated claims on Vyepti migraine webpagesThe U.S. Food and Drug Administration issued an untitled letter to Lundbeck Seattle Biopharmaceuticals criticizing two promotional webpages about its migraine treatment Vyepti. The agency said the…
- GSK ends $2.2 billion brain drug partnership with Alector after trial failuresGSK and California‑based biotech Alector have ended their collaboration after both experimental brain drugs failed to meet development milestones. The partnership, announced in July 2021, gave GSK…